Inspire Medical Systems, Inc. (INSP) |
| 92.46 -4.47 (-4.61%) 01-13 16:00 |
| Open: | 98.31 |
| High: | 98.31 |
| Low: | 91.425 |
| Volume: | 718,563 |
| Market Cap: | 2,736(M) |
| PE Ratio: | 63.33 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 147.03 |
| Resistance 1: | 125.22 |
| Pivot price: | 95.24 |
| Support 1: | 89.94 |
| Support 2: | 74.83 |
| 52w High: | 203.12 |
| 52w Low: | 70.77 |
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
| EPS | 1.460 |
| Book Value | 22.940 |
| PEG Ratio | 0.00 |
| Gross Profit | 25.791 |
| Profit Margin (%) | 5.05 |
| Operating Margin (%) | 4.30 |
| Return on Assets (ttm) | 2.9 |
| Return on Equity (ttm) | 6.5 |
Tue, 13 Jan 2026
Insider Sell: John Rondoni Sells Shares of Inspire Medical Syste - GuruFocus
Tue, 13 Jan 2026
Inspire Medical Systems appoints Matt Osberg as new CFO By Investing.com - Investing.com Nigeria
Mon, 12 Jan 2026
Inspire Medical Systems Issues Strong Preliminary 2025 Revenue Results - TipRanks
Mon, 12 Jan 2026
Inspire Medical Systems (NYSE: INSP) sets CFO transition, preliminary 2025 results - Stock Titan
Mon, 12 Jan 2026
Inspire Medical Systems (INSP) Reports Strong Revenue Growth in 2025 - GuruFocus
Mon, 12 Jan 2026
Inspire Medical Systems, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full Year 2025 and Provides Initial 2026 Revenue Guidance - Chartmill
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |